CURx Pharma Joins Gilead to Develop FTI for a CF-Related Lung Infection
CURx Pharmaceuticals will team up with Gilead Sciences in developing its broad spectrum combination antibiotic Fosfomycin:Tobramycin for Inhalation (FTI) to treat a form of lung infection in cystic fibrosis (C…
Read guide →